Quick note for new folks Miami name means they presented at the marathon Miami healthcare week which i broke down

52-Week Highs and Lows, March 31, 2026

4 new highs, 5 new lows. Mixed day. The highs are quality names with real momentum.

New 52-Week Highs

PFE $28.31. Pfizer making new highs. Large cap pharma buyer sitting on tens of billions in cash. When big pharma stock prices are running hot, they go shopping. Good signal for the M&A thesis across the board.

KALV $20.58. Tier 3 Miami name. Hereditary angioedema oral prophylaxis, competing with BioCryst and Takeda. Steady grind higher continues. Back-to-back weeks of new highs.

ETON $24.90. Tier 3 Miami name. Specialty pharma with a growing commercial portfolio. Two Miami Tier 3 names hitting new highs in the same session is worth noting.

ORKA $49.32. Anti-IL-23 for psoriasis with potential once-yearly dosing. ~100-day half-life. EVERLAST-A 16-week data coming Q2 2026. If yearly dosing validates, every derm buyer comes calling. Running hard into the catalyst. $2.2B market cap, $479M cash.

New 52-Week Lows

ABT $100.88. Abbott Labs. Large cap medtech/diagnostics hitting new lows. Tariff and macro pressure dragging diversified healthcare names. Not bio M&A relevant but sector sentiment reads negative.

NSRX $1.98. Tier 3 Miami name. Phase 2 data on NS002 (intranasal epinephrine) was positive March 16, beat EpiPen on speed. Stock still can't catch a bid. Getting into sub-$2 danger territory.

RVPH $0.59. Reviva Pharmaceuticals. Sub-dollar, death spiral zone. Not actionable.

PSTV $0.16. Plus Therapeutics. Same. Sub-dollar, watching only.

AGMB $9.63. AgomAb Therapeutics. MET-targeting antibody platform for fibrosis and IBD. Belgian biotech. Early clinical stage. Second day in a row hitting new lows. $480M market cap still has some floor from the platform value but trend is ugly.

Miami list names on both sides again. KALV and ETON confirming momentum on the highs, NSRX continuing to bleed on the lows despite positive data. ORKA running into the Q2 catalyst is the most interesting name on the highs side. PFE at new highs is the macro signal, big pharma with cash to deploy is fuel for small cap M&A.